Collegium Pharmaceutical Inc
COLL
Get informed when a big investor buys or sells
+ FollowMarket Cap$737.87M
Close$
$17.40
22.2% downside
Current Fair Value
22.2% downsideOvervalued by 22.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $737.87 Million |
|---|---|
| Enterprise Value | $1.47 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.98 |
| Beta | 0.72 |
| Outstanding Shares | 32,460,783 |
Return
| Return on Equity | 15.36% |
|---|---|
| Return on Assets | 2.24% |
| Return on Invested Capital | 15.13% |
Valuation & Multiples
| P/E Ratio | 14.87 |
|---|---|
| PEG | -6.59 |
| Price to Sales | 0.93 |
| Price to Book Ratio | 2.49 |
| Enterprise Value to Revenue | 1.81 |
| Enterprise Value to EBIT | 6.27 |
| Enterprise Value to Net Income | 30 |
| Total Debt to Enterprise | 0.59 |
| Debt to Equity | 2.75 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$1.72
Average shareholder expectationRevenue Estimate
$199.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$1.80
Average shareholder expectationRevenue Estimate
$217.97 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9076▲ 190.76% |
|---|---|
| Total Calls | 24,900▲ Infinity% |
| Total Puts | 47,500▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 122.10%▲ 3.73% |
|---|---|
| Total Invested | $1.43B▲ 14.20% |
| Investors Holding | 283▲ 16.00% |
ESG Score
No data
About Collegium Pharmaceutical Inc
CEO: Joseph Ciaffoni